Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BNB PLUS CORP.BNBX · Entity 8621 | Director | March 27, 2026 | March 31, 2026 |
| BioRestorative Therapies, Inc.BRTX · Entity 8277 | Director | March 25, 2019 | March 27, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BNB PLUS CORP.
Report date March 27, 2026 · Filed March 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.69 · Expires 2036-03-27 | Direct | 77,038 |
Reported balance
After 2026-03-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-27 · Grant · Acquired 77,038 · Balance 77,038 F1: The options vest 25% on the grant date, then 25% per quarter commencing 90 days from the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest 25% on the grant date, then 25% per quarter commencing 90 days from the grant date.
BioRestorative Therapies, Inc.
Report date March 25, 2019 · Filed March 27, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.70 · Expires 2026-02-19 | Direct | 0 |
Reported balance
After 2019-03-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-03-25 · Disposition to issuer · Disposed 15,000 · Balance 0 F5: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1: The option vests to the extent of 5,000 shares on each of February 19, 2017, 2018 and 2019. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2026-02-19 | Direct | 15,000 |
Reported balance
After 2019-03-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-03-25 · Grant · Acquired 15,000 · Balance 15,000 F5: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1: The option vests to the extent of 5,000 shares on each of February 19, 2017, 2018 and 2019. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.73 · Expires 2026-06-10 | Direct | 0 |
Reported balance
After 2019-03-25 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-03-25 · Disposition to issuer · Disposed 29,000 · Balance 0 F5: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2: The option vests to the extent of 9,667 shares on each of June 10, 2016 and June 10, 2017, and 9,666 shares on June 10, 2018. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2026-06-10 | Direct | 29,000 |
Reported balance
After 2019-03-25 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-03-25 · Grant · Acquired 29,000 · Balance 29,000 F5: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2: The option vests to the extent of 9,667 shares on each of June 10, 2016 and June 10, 2017, and 9,666 shares on June 10, 2018. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2027-06-23 | Direct | 0 |
Reported balance
After 2019-03-25 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-03-25 · Disposition to issuer · Disposed 100,000 · Balance 0 F5: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F3: The option is exercisable to the extent of 33,334 shares on June 23, 2017, and 33,333 shares on each of June 23, 2018 and June 23, 2019. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2027-06-23 | Direct | 100,000 |
Reported balance
After 2019-03-25 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-03-25 · Grant · Acquired 100,000 · Balance 100,000 F5: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F3: The option is exercisable to the extent of 33,334 shares on June 23, 2017, and 33,333 shares on each of June 23, 2018 and June 23, 2019. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2028-10-29 | Direct | 0 |
Reported balance
After 2019-03-25 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2019-03-25 · Disposition to issuer · Disposed 75,000 · Balance 0 F5: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4: The option is exercisable to the extent of 25,000 shares on each of October 29, 2018, October 29, 2019 and October 29, 2020. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2028-10-29 | Direct | 75,000 |
Reported balance
After 2019-03-25 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2019-03-25 · Grant · Acquired 75,000 · Balance 75,000 F5: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4: The option is exercisable to the extent of 25,000 shares on each of October 29, 2018, October 29, 2019 and October 29, 2020. |
| Common StockSEC Table I · non-derivative | Direct | 80,866 |
Reported balance
Holding disclosure · report date 2019-03-25 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 80,866 |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2021-03-01 | Direct | 37,500 |
Reported balance
Holding disclosure · report date 2019-03-25 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 37,500 |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2021-05-18 | Direct | 12,500 |
Reported balance
Holding disclosure · report date 2019-03-25 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 12,500 |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2021-08-05 | Direct | 8,000 |
Reported balance
Holding disclosure · report date 2019-03-25 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 8,000 |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2022-02-10 | Direct | 10,866 |
Reported balance
Holding disclosure · report date 2019-03-25 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 10,866 |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2022-03-01 | Direct | 15,000 |
Reported balance
Holding disclosure · report date 2019-03-25 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 15,000 |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2022-08-11 | Direct | 5,000 |
Reported balance
Holding disclosure · report date 2019-03-25 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 5,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests to the extent of 5,000 shares on each of February 19, 2017, 2018 and 2019.
F2: The option vests to the extent of 9,667 shares on each of June 10, 2016 and June 10, 2017, and 9,666 shares on June 10, 2018.
F3: The option is exercisable to the extent of 33,334 shares on June 23, 2017, and 33,333 shares on each of June 23, 2018 and June 23, 2019.
F4: The option is exercisable to the extent of 25,000 shares on each of October 29, 2018, October 29, 2019 and October 29, 2020.
F5: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 27, 2026 Filed Mar 31, 2026 20:08 UTC | BNB PLUS CORP. BNBX · Entity 8621 | GrantIncentive Stock Option (right to buy) · Derivative | 77,038 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001104659-26-037722 · tm2610688-5_4seq1.xml · derivative · entry 1 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,038 Underlying: Common Stock · 77,038 shares Expires 2036-03-27 F1 · derivative.exercise_date: The options vest 25% on the grant date, then 25% per quarter commencing 90 days from the grant date. Read SEC document |
| October 17, 2025 Filed Oct 20, 2025 21:04 UTC | BNB PLUS CORP. BNBX · Entity 8621 | GrantCommon Stock | 22,511 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-100878 · tm2529089-7_4seq1.xml · nonDerivative · entry 1 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,512 F1 · security: 100% of the restricted stock units vest upon 90 days from the date of grant Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 21:16 UTC | BNB PLUS CORP. APDN · Entity 8621 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 39,428 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001104659-23-007532 · tm234563-1_4seq1.xml · derivative · entry 2 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,428 Underlying: Common Stock · 39,428 shares Expires 2033-01-25 F1 · derivative.exercise_date: These options vest in full and become exercisable on the first anniversary of the date of grant, subject to continued board membership through such date. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 21:16 UTC | BNB PLUS CORP. APDN · Entity 8621 | GrantIncentive Stock Option (right to buy) · Derivative | 75,099 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001104659-23-007532 · tm234563-1_4seq1.xml · derivative · entry 1 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,099 Underlying: Common Stock · 75,099 shares Expires 2033-01-25 F1 · derivative.exercise_date: These options vest in full and become exercisable on the first anniversary of the date of grant, subject to continued board membership through such date. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:47 UTC | BNB PLUS CORP. APDN · Entity 8621 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 9,948 | $0.00 Strike: $5.58 | $0.00 |
DisclosureSEC source: 0001104659-21-133699 · tm2131758-8_4seq1.xml · derivative · entry 2 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,948 Underlying: Common Stock · 9,948 shares Expires 2031-10-31 F1 · derivative.exercise_date: These options vest in full and become exercisable on the first anniversary of the date of grant, subject to continued board membership through such date. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:47 UTC | BNB PLUS CORP. APDN · Entity 8621 | GrantIncentive Stock Option (right to buy) · Derivative | 19,897 | $0.00 Strike: $5.58 | $0.00 |
DisclosureSEC source: 0001104659-21-133699 · tm2131758-8_4seq1.xml · derivative · entry 1 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,897 Underlying: Common Stock · 19,897 shares Expires 2031-10-31 F1 · derivative.exercise_date: These options vest in full and become exercisable on the first anniversary of the date of grant, subject to continued board membership through such date. Read SEC document |
| May 22, 2020 Filed May 27, 2020 20:09 UTC | BNB PLUS CORP. APDN · Entity 8621 | GrantStock Option (right to buy) · Derivative | 13,606 | $0.00 Strike: $11.04 | $0.00 |
DisclosureSEC source: 0001104659-20-066395 · tm2020994-2_4.xml · derivative · entry 1 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,606 Underlying: Common Stock · 13,606 shares Expires 2030-05-21 F1 · derivative.exercise_date: These options vest in full and become exercisable on the first anniversary of the date of grant, subject to continued board membership through such date. Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 20:02 UTC | BNB PLUS CORP. APDN · Entity 8621 | OtherSecured Convertible Note · Derivative | 26,549 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001144204-19-044707 · tv529471_4.xml · derivative · entry 2 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,165 shares Expires 2021-11-28 Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 20:02 UTC | BNB PLUS CORP. APDN · Entity 8621 | OtherCommon Stock | 49,165 | $0.54 | $26,549.10 |
DisclosureSEC source: 0001144204-19-044707 · tv529471_4.xml · nonDerivative · entry 1 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,575 F1 · shares: The shares were issued as a result of the conversion of $26,549 of secured convertible notes that were originally issued on August 31, 2019 and represent the outstanding principal and interest of such secured convertible notes. Read SEC document |
| May 17, 2019 Filed May 21, 2019 20:02 UTC | BNB PLUS CORP. APDN · Entity 8621 | GrantStock Option (right to buy) · Derivative | 198,826 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001144204-19-027500 · tv522082_4.xml · derivative · entry 1 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,826 Underlying: Common Stock · 198,826 shares Expires 2029-05-16 F1 · derivative.exercise_date: These options vest in full and become exercisable on the first anniversary of the date of grant, subject to continued board membership through such date. Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 17:11 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 75,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007726 · doc1.xml · derivative · entry 15 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-10-29 F5 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4 · derivative.exercise_date: The option is exercisable to the extent of 25,000 shares on each of October 29, 2018, October 29, 2019 and October 29, 2020. Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 17:11 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 75,000 | Not disclosed Strike: $1.23 | Not disclosed |
DisclosureSEC source: 0001567619-19-007726 · doc1.xml · derivative · entry 14 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2028-10-29 F5 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4 · derivative.exercise_date: The option is exercisable to the extent of 25,000 shares on each of October 29, 2018, October 29, 2019 and October 29, 2020. Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 17:11 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 100,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007726 · doc1.xml · derivative · entry 12 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-06-23 F5 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F3 · derivative.exercise_date: The option is exercisable to the extent of 33,334 shares on June 23, 2017, and 33,333 shares on each of June 23, 2018 and June 23, 2019. Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 17:11 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 100,000 | Not disclosed Strike: $3.35 | Not disclosed |
DisclosureSEC source: 0001567619-19-007726 · doc1.xml · derivative · entry 11 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2027-06-23 F5 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F3 · derivative.exercise_date: The option is exercisable to the extent of 33,334 shares on June 23, 2017, and 33,333 shares on each of June 23, 2018 and June 23, 2019. Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 17:11 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 29,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007726 · doc1.xml · derivative · entry 7 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,000 Underlying: Common Stock · 29,000 shares Expires 2026-06-10 F5 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2 · derivative.exercise_date: The option vests to the extent of 9,667 shares on each of June 10, 2016 and June 10, 2017, and 9,666 shares on June 10, 2018. Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 17:11 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 29,000 | Not disclosed Strike: $3.73 | Not disclosed |
DisclosureSEC source: 0001567619-19-007726 · doc1.xml · derivative · entry 6 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,000 shares Expires 2026-06-10 F5 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2 · derivative.exercise_date: The option vests to the extent of 9,667 shares on each of June 10, 2016 and June 10, 2017, and 9,666 shares on June 10, 2018. Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 17:11 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 15,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007726 · doc1.xml · derivative · entry 3 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2026-02-19 F5 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1 · derivative.exercise_date: The option vests to the extent of 5,000 shares on each of February 19, 2017, 2018 and 2019. Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 17:11 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 15,000 | Not disclosed Strike: $3.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007726 · doc1.xml · derivative · entry 2 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-02-19 F5 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1 · derivative.exercise_date: The option vests to the extent of 5,000 shares on each of February 19, 2017, 2018 and 2019. Read SEC document |
| October 29, 2018 Filed Oct 30, 2018 18:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 75,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001567619-18-004802 · doc1.xml · derivative · entry 11 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-10-29 F4 · derivative.exercise_date: The option is exercisable to the extent of 25,000 shares on each of October 29, 2018, October 29, 2019 and October 29, 2020. Read SEC document |
| August 31, 2018 Filed Oct 10, 2018 01:25 UTC | BNB PLUS CORP. APDN · Entity 8621 | ConversionSecured Convertible Note · Derivative | 25,000 | Not disclosed Strike: $2.50 | Not disclosed |
DisclosureSEC source: 0001144204-18-053074 · tv504557_form4.xml · derivative · entry 1 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 10,000 shares Expires 2021-08-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Secured convertible note was issued in an exempt transaction pursuant to a securities purchase agreement dated August 31, 2018 at a purchase price of 100% of its principal balance. Read SEC document |
| August 31, 2018 Filed Jul 18, 2019 20:44 UTC Amendment | BNB PLUS CORP. APDN · Entity 8621 | ConversionSecured Convertible Note · Derivative | 25,000 | Not disclosed Strike: $2.50 | Not disclosed |
DisclosureSEC source: 0001144204-19-035071 · tv525335_form4a.xml · derivative · entry 1 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 48,391 shares Expires 2021-11-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Secured convertible note was issued in an exempt transaction pursuant to a securities purchase agreement dated August 31, 2018 at a purchase price of 100% of its principal balance. On July 16, 2019 an amendment to the Secured convertible note was entered into, to, among other things, (i) amend the conversion price to $0.54 from $2.50 and (ii) amend the maturity date of the August 2018 Notes to November 28, 2021. Read SEC document |
| May 09, 2018 Filed May 10, 2018 10:33 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 5,000 | $2.80 | $14,000.00 |
DisclosureSEC source: 0001140361-18-022682 · doc1.xml · nonDerivative · entry 1 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,866 Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 20:09 UTC | BNB PLUS CORP. APDN · Entity 8621 | GrantStock Option (right to buy) · Derivative | 74,572 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001144204-18-015587 · tv488781_form4.xml · derivative · entry 1 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,572 Underlying: Common Stock · 74,572 shares Expires 2028-03-14 F1 · derivative.exercise_date: These options vest in full and become exercisable on the first anniversary of the date of grant, subject to continued board membership through such date. Read SEC document |
| August 11, 2017 Filed Aug 14, 2017 16:44 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantWarrant · Derivative | 5,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001140361-17-032071 · doc1.xml · derivative · entry 10 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2022-08-11 F4 · price: The Warrant was issued in consideration of an extension of the maturity date of a promissory note issued by the Issuer. Read SEC document |
| June 28, 2017 Filed Jun 29, 2017 23:08 UTC | BNB PLUS CORP. APDN · Entity 8621 | GrantCommon Stock | 28,410 | $1.76 | $50,001.60 |
DisclosureSEC source: 0001571049-17-006375 · t1700414h-catell0628.xml · nonDerivative · entry 1 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,410 Read SEC document |
| June 23, 2017 Filed Jun 27, 2017 17:20 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001140361-17-026291 · doc1.xml · derivative · entry 9 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-06-23 F3 · derivative.exercise_date: The option is exercisable to the extent of 33,334 shares on June 23, 2017, and 33,333 shares on each of June 23, 2018 and June 23, 2019. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 09:57 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantWarrant · Derivative | 15,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001140361-17-010412 · doc1.xml · derivative · entry 8 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2022-03-01 F1 · price: In exchange for accrued director fees. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 09:57 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantCommon Stock | 15,000 | $3.00 | $45,000.00 |
DisclosureSEC source: 0001140361-17-010412 · doc1.xml · nonDerivative · entry 1 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,866 F1 · price: In exchange for accrued director fees. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 11:20 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantWarrant · Derivative | 10,866 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001140361-17-006660 · doc1.xml · derivative · entry 7 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,866 Underlying: Common Stock · 10,866 shares Expires 2022-02-10 F3 · price: The warrant was issued in consideration of a concurrent acquisition by the Reporting Person from the Issuer of 10,866 shares. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 11:20 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantCommon Stock | 10,866 | $3.00 | $32,598.00 |
DisclosureSEC source: 0001140361-17-006660 · doc1.xml · nonDerivative · entry 1 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,866 Read SEC document |
| December 20, 2016 Filed Dec 22, 2016 21:09 UTC | BNB PLUS CORP. APDN · Entity 8621 | GrantStock Option (right to buy) · Derivative | 50,758 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001571049-16-020819 · t1600811h-catell1220.xml · derivative · entry 1 CATELL ROBERT B · CIK 0001195325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,758 Underlying: Common Stock · 50,758 shares Expires 2026-12-19 F1 · derivative.exercise_date: These options vest in full and become exercisable on the first anniversary of the date of grant, subject to continued board membership through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.